The tissue heart valves market size has grown steadily in recent years. It will grow from $1.52 billion in 2025 to $1.56 billion in 2026 at a compound annual growth rate (CAGR) of 2.6%. The growth in the historic period can be attributed to growth in cardiovascular diseases, limitations of mechanical valves, surgical valve replacement adoption, hospital cardiac infrastructure, aging demographics.
The tissue heart valves market size is expected to see steady growth in the next few years. It will grow to $1.72 billion in 2030 at a compound annual growth rate (CAGR) of 2.5%. The growth in the forecast period can be attributed to expansion of TAVR procedures, minimally invasive cardiac surgery growth, longer valve durability innovation, rising healthcare access, cardiology specialization growth. Major trends in the forecast period include preference for bioprosthetic valves, rising transcatheter valve procedures, improved tissue preservation techniques, reduced long-term anticoagulation use, aging population valve replacement demand.
The increasing prevalence of cardiovascular diseases (CVDs) is expected to drive the growth of the tissue heart valves market in the coming years. CVDs, which include conditions such as heart attacks, strokes, and hypertension, are among the leading causes of mortality worldwide. This rise is primarily driven by unhealthy lifestyles, aging populations, increased prevalence of risk factors, poor diets, physical inactivity, smoking, stress, and urbanization, all contributing to higher rates of heart-related disorders. Tissue heart valves play a crucial role in treating cardiovascular diseases by offering a biocompatible, durable, and less thrombogenic solution for patients requiring valve replacement, ultimately improving long-term heart function and reducing complications. For example, in September 2024, a report by the Heart Failure Society of America (HFSA) stated that approximately 6.7 million Americans aged 20 and older are living with heart failure (HF), with projections estimating this number to rise to 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050. This rising burden of CVDs is fueling the demand for tissue heart valves.
Companies operating in the tissue heart valves market are focusing on technological innovations to improve patient outcomes. For instance, in June 2024, Medtronic plc, an Ireland-based technology company, launched the Avalus Ultra valve, a next-generation surgical aortic tissue valve designed to enhance ease of use during implantation and support long-term patient management. This valve, built on a decade of clinical experience with the Avalus valve, features a low profile, a polyetheretherketone (PEEK) base frame for consistent circularity, and an industry-leading Effective Orifice Area (EOA) to improve blood flow. Additionally, it includes a radiopaque coil for better visibility in future valve-in-valve procedures, ensuring long-term durability for patients with aortic stenosis.
In February 2024, Foldax Inc., a US-based medical device company, partnered with Dolphin Life Science India LLP to manufacture the Tria polymer mitral surgical heart valve in India. This collaboration enables in-country production and distribution, making advanced heart valve solutions more accessible to patients. Dolphin Life Science India LLP is an India-based life sciences company specializing in heart valve manufacturing and distribution.
Major companies operating in the tissue heart valves market are Abbott Laboratories, Medtronic PLC, Edwards Lifesciences Corporation, LivaNova PLC, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, LifeNet Health Inc., TTK Healthcare Ltd., Braile Biomédica, Anteris Technologies Ltd., Labcor Laboratórios Ltd., CARDION s.r.o., CryoLife Inc., Colibri Heart Valve LLC, Foldax Inc., Balance Medical Technologies Co. Ltd., MiCardia Corporation, St. Jude Medical Inc., Sorin Group, Hancock J & Co.
North America was the largest region in the tissue heart valves market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tissue heart valves market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tissue heart valves market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the tissue heart valves market by increasing costs of processed biological tissues, precision stents, and sterilization technologies. Stented tissue valve segments and aortic valve replacements are most impacted, especially in North America and Europe. While tariffs elevate device pricing, they also promote localized valve manufacturing, improved supply-chain control, and innovation in cost-efficient bioprosthetic valve designs.
The tissue heart valves market research report is one of a series of new reports that provides tissue heart valves market statistics, including tissue heart valves industry global market size, regional shares, competitors with a tissue heart valves market share, detailed tissue heart valves market segments, market trends and opportunities, and any further data you may need to thrive in the tissue heart valves industry. This tissue heart valves market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Tissue heart valves are biological heart valves used in replacement surgeries, designed to function such as natural heart valves as an alternative to mechanical ones.
The primary types of tissue heart valves are stented and stentless valves. Stented tissue heart valves are bioprosthetic valves reinforced with a metal or polymer frame (stent) to provide structural support and simplify implantation during valve replacement procedures. These valves come in various types, including aortic, mitral, tricuspid, and pulmonary valves. They are utilized by multiple end-users, such as hospitals, ambulatory surgical centers, and other medical facilities.
The tissue heart valves market consists of sales of porcine xenograft valves, bovine pericardial valves, and autograft valves. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The tissue heart valves market size is expected to see steady growth in the next few years. It will grow to $1.72 billion in 2030 at a compound annual growth rate (CAGR) of 2.5%. The growth in the forecast period can be attributed to expansion of TAVR procedures, minimally invasive cardiac surgery growth, longer valve durability innovation, rising healthcare access, cardiology specialization growth. Major trends in the forecast period include preference for bioprosthetic valves, rising transcatheter valve procedures, improved tissue preservation techniques, reduced long-term anticoagulation use, aging population valve replacement demand.
The increasing prevalence of cardiovascular diseases (CVDs) is expected to drive the growth of the tissue heart valves market in the coming years. CVDs, which include conditions such as heart attacks, strokes, and hypertension, are among the leading causes of mortality worldwide. This rise is primarily driven by unhealthy lifestyles, aging populations, increased prevalence of risk factors, poor diets, physical inactivity, smoking, stress, and urbanization, all contributing to higher rates of heart-related disorders. Tissue heart valves play a crucial role in treating cardiovascular diseases by offering a biocompatible, durable, and less thrombogenic solution for patients requiring valve replacement, ultimately improving long-term heart function and reducing complications. For example, in September 2024, a report by the Heart Failure Society of America (HFSA) stated that approximately 6.7 million Americans aged 20 and older are living with heart failure (HF), with projections estimating this number to rise to 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050. This rising burden of CVDs is fueling the demand for tissue heart valves.
Companies operating in the tissue heart valves market are focusing on technological innovations to improve patient outcomes. For instance, in June 2024, Medtronic plc, an Ireland-based technology company, launched the Avalus Ultra valve, a next-generation surgical aortic tissue valve designed to enhance ease of use during implantation and support long-term patient management. This valve, built on a decade of clinical experience with the Avalus valve, features a low profile, a polyetheretherketone (PEEK) base frame for consistent circularity, and an industry-leading Effective Orifice Area (EOA) to improve blood flow. Additionally, it includes a radiopaque coil for better visibility in future valve-in-valve procedures, ensuring long-term durability for patients with aortic stenosis.
In February 2024, Foldax Inc., a US-based medical device company, partnered with Dolphin Life Science India LLP to manufacture the Tria polymer mitral surgical heart valve in India. This collaboration enables in-country production and distribution, making advanced heart valve solutions more accessible to patients. Dolphin Life Science India LLP is an India-based life sciences company specializing in heart valve manufacturing and distribution.
Major companies operating in the tissue heart valves market are Abbott Laboratories, Medtronic PLC, Edwards Lifesciences Corporation, LivaNova PLC, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, LifeNet Health Inc., TTK Healthcare Ltd., Braile Biomédica, Anteris Technologies Ltd., Labcor Laboratórios Ltd., CARDION s.r.o., CryoLife Inc., Colibri Heart Valve LLC, Foldax Inc., Balance Medical Technologies Co. Ltd., MiCardia Corporation, St. Jude Medical Inc., Sorin Group, Hancock J & Co.
North America was the largest region in the tissue heart valves market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tissue heart valves market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tissue heart valves market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the tissue heart valves market by increasing costs of processed biological tissues, precision stents, and sterilization technologies. Stented tissue valve segments and aortic valve replacements are most impacted, especially in North America and Europe. While tariffs elevate device pricing, they also promote localized valve manufacturing, improved supply-chain control, and innovation in cost-efficient bioprosthetic valve designs.
The tissue heart valves market research report is one of a series of new reports that provides tissue heart valves market statistics, including tissue heart valves industry global market size, regional shares, competitors with a tissue heart valves market share, detailed tissue heart valves market segments, market trends and opportunities, and any further data you may need to thrive in the tissue heart valves industry. This tissue heart valves market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Tissue heart valves are biological heart valves used in replacement surgeries, designed to function such as natural heart valves as an alternative to mechanical ones.
The primary types of tissue heart valves are stented and stentless valves. Stented tissue heart valves are bioprosthetic valves reinforced with a metal or polymer frame (stent) to provide structural support and simplify implantation during valve replacement procedures. These valves come in various types, including aortic, mitral, tricuspid, and pulmonary valves. They are utilized by multiple end-users, such as hospitals, ambulatory surgical centers, and other medical facilities.
The tissue heart valves market consists of sales of porcine xenograft valves, bovine pericardial valves, and autograft valves. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Tissue Heart Valves Market Characteristics
3. Tissue Heart Valves Market Supply Chain Analysis
4. Global Tissue Heart Valves Market Trends and Strategies
5. Tissue Heart Valves Market Analysis of End Use Industries
7. Global Tissue Heart Valves Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Tissue Heart Valves Total Addressable Market (TAM) Analysis for the Market
9. Tissue Heart Valves Market Segmentation
10. Tissue Heart Valves Market Regional and Country Analysis
11. Asia-Pacific Tissue Heart Valves Market
12. China Tissue Heart Valves Market
13. India Tissue Heart Valves Market
14. Japan Tissue Heart Valves Market
15. Australia Tissue Heart Valves Market
16. Indonesia Tissue Heart Valves Market
17. South Korea Tissue Heart Valves Market
18. Taiwan Tissue Heart Valves Market
19. South East Asia Tissue Heart Valves Market
20. Western Europe Tissue Heart Valves Market
21. UK Tissue Heart Valves Market
22. Germany Tissue Heart Valves Market
23. France Tissue Heart Valves Market
24. Italy Tissue Heart Valves Market
25. Spain Tissue Heart Valves Market
26. Eastern Europe Tissue Heart Valves Market
27. Russia Tissue Heart Valves Market
28. North America Tissue Heart Valves Market
29. USA Tissue Heart Valves Market
30. Canada Tissue Heart Valves Market
31. South America Tissue Heart Valves Market
32. Brazil Tissue Heart Valves Market
33. Middle East Tissue Heart Valves Market
34. Africa Tissue Heart Valves Market
36. Tissue Heart Valves Market Competitive Landscape and Company Profiles
37. Tissue Heart Valves Market Other Major and Innovative Companies
40. Tissue Heart Valves Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Tissue Heart Valves Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses tissue heart valves market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for tissue heart valves? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tissue heart valves market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Stented Tissue Heart Valves; Stentless Tissue Heart Valves2) By Procedure Type: Surgical Aortic Valve Replacement (SAVR); Transcatheter Aortic Valve Replacement (TAVR)
3) By End-User: Hospitals; Ambulatory Surgical Centers; Other End-Users
Subsegments:
1) By Stented Tissue Heart Valves: Bovine Pericardial Valves; Porcine Valves2) By Stentless Tissue Heart Valves: Bovine Pericardial Stentless Valves; Homograft Valves
Companies Mentioned: Abbott Laboratories; Medtronic PLC; Edwards Lifesciences Corporation; LivaNova PLC; Meril Life Sciences Pvt. Ltd.; MicroPort Scientific Corporation; LifeNet Health Inc.; TTK Healthcare Ltd.; Braile Biomédica; Anteris Technologies Ltd.; Labcor Laboratórios Ltd.; CARDION s.r.o.; CryoLife Inc.; Colibri Heart Valve LLC; Foldax Inc.; Balance Medical Technologies Co. Ltd.; MiCardia Corporation; St. Jude Medical Inc.; Sorin Group; Hancock J & Co.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Tissue Heart Valves market report include:- Abbott Laboratories
- Medtronic PLC
- Edwards Lifesciences Corporation
- LivaNova PLC
- Meril Life Sciences Pvt. Ltd.
- MicroPort Scientific Corporation
- LifeNet Health Inc.
- TTK Healthcare Ltd.
- Braile Biomédica
- Anteris Technologies Ltd.
- Labcor Laboratórios Ltd.
- CARDION s.r.o.
- CryoLife Inc.
- Colibri Heart Valve LLC
- Foldax Inc.
- Balance Medical Technologies Co. Ltd.
- MiCardia Corporation
- St. Jude Medical Inc.
- Sorin Group
- Hancock J & Co.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.56 Billion |
| Forecasted Market Value ( USD | $ 1.72 Billion |
| Compound Annual Growth Rate | 2.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
